22:35 , Jul 11, 2019 |  BC Innovations  |  Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

Twentyeight-Seven is building a small molecule platform to target interactions between non-coding RNAs and an emerging target class in gene regulation: RNA-binding proteins. Launched last September, the company is using an $82.8 million series A...
17:46 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million on Sept. 6 in a series A round co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC, Longwood Fund and...
21:22 , Sep 6, 2018 |  BC Extra  |  Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million in a series A co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC, Longwood Fund and Astellas Venture Management also...
07:00 , May 19, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Sirtuin 6 (SIRT6); lin-28 homolog B (LIN28B)

Cancer INDICATION: Pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting LIN28B could help treat pancreatic ductal adenocarcinomas (PDACs) harboring loss-of-function SIRT6 mutations. In 30-40% of PDAC patients, SIRT6 levels were lower in...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Lin-28 homolog A (LIN28A)-dependent metabolic reprogramming for tissue repair Mouse studies suggest elevating LIN28A activity could help promote tissue regeneration after injury or in advanced...
08:00 , Feb 18, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Approach

Approach Summary Licensing status Publication and contact information Drug delivery Nonviral vector for induced pluripotent stem (iPS) cells In vitro and mouse studies suggest that a nonviral DNA vector could be useful for delivering genes...
07:00 , Jun 11, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Lin-28 homolog (LIN28); Lin-28 homolog B (LIN28B) In vitro studies suggest that targeting LIN28 and LIN28B could help treat cancer....